Phase 2 Kidney Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with kidney cancer (renal cell carcinoma) that has spread or cannot be removed or cured by surgery or radiation, confirmed by a tissue biopsy or lab test
- People with the clear cell type of kidney cancer, or in the early part of the trial (Part 1), people with other types of kidney cancer may also be considered
- People whose kidney cancer is classified as low, medium, or high risk
- People who have not previously received systemic (whole-body) treatment for their kidney cancer that has spread, with some exceptions: one prior treatment given before or after surgery may be allowed if it did not target a protein called VEGF and if the cancer came back at least 6 months after that treatment ended; in certain parts of the trial, some prior treatments in the advanced setting may be allowed (confirm with trial site)
- People who have at least one area of cancer that can be measured on a scan, according to standard measurement guidelines
Who may not be able to join:
- People who have cancer that has spread to the brain or spinal cord (central nervous system) that has not yet been treated
- People who are currently taking high-dose steroid medications or other drugs that suppress the immune system (within the 14 days before starting the trial)
- People who have a history of scarring or inflammation in the lungs (interstitial lung disease or pneumonitis)
- People with ongoing fluid build-up around the lungs or heart that keeps needing to be drained
- People who have had a heart attack, unstable chest pain, stroke, or blood clot in an artery within the past 6 months, or who have high blood pressure that is not well controlled, or a heart condition called congenital long QT syndrome
- People with too much protein in their urine at the start of the trial, as measured by specific lab tests
- People with significant problems with blood clotting
- People who have had a serious blood clot, such as a deep vein thrombosis or a clot in the lungs, within the past 6 months
- People who have had a hole or abnormal opening in their bowel or abdomen within the past 6 months
- People who have had a major surgery or serious physical injury within the 28 days before starting the trial
- There may be additional criteria not listed here (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb
Phone: 855-907-3286
Australian sites
+61298123526
61294631172
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Number of participants with adverse events (AEs); Number of participants with serious adverse events (SAEs) (as per Common Terminology Criteria for Adverse Events v5 (CTCAE v5)); Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria; Number of participants with AEs leading to discontinuation; Number of participants with AEs leading to death; Objective response rate (ORR) (confirmed complete response (CR) or partial response (PR)) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 per investigator assessment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.